Company intelligence / Profile preview

CANNADORF

Ownership: Private
Development stage: Preclinical

Overview

CANNADORF develops a proprietary platform using sterile cannabis tissue culture grown in bioreactors under cGMP conditions to manufacture consistent, pharma-grade cannabinoids and related plant APIs. Their technology enables precise control over cannabinoid profiles via genome editing and aims to supply pharmaceutical companies with safe, reproducible extracts or APIs without the limitations of traditional agriculture. The company positions itself as a breakthrough provider of high-quality plant-derived actives for pharmaceuticals, nutraceuticals, and cosmeceuticals.

Therapeutic areas: Other
Modalities: Plant-derived active pharmaceutical ingredients (APIs)Cannabinoids, terpenes, flavonoidsGenome-edited plant tissue cultures
Industry: Contract Manufacturing Organization

Drug pipeline

1 asset

ibogaine + citalopram

Pre-clinical

Indications: Depression

Beyond the preview

Go deeper on CANNADORF.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CANNADORF.

Explore the full profile